Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02218125 · ClinicalTrials.gov registry record · Phase 1
A Phase I Study of an HIV Vaccine in Healthy, HIV Uninfected Adults
A Phase 1 study of Healthy, sponsored by Crucell Holland.
- Completed
- Registry status
- Phase 1
- Development phase
- 25
- Enrollment target
- 1
- Study location
NCT02218125: Completed Phase 1 study of Healthy, sponsored by Crucell Holland.
NCT02218125 is a Phase 1 study of Healthy that has completed, run by Crucell Holland. The registered enrollment target is 25 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02218125, a Phase 1 study of Healthy, has completed, sponsored by Crucell Holland.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 25 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to assess the safety and tolerability of Modified Vaccinia Ankara (MVA) Mosaic vaccine in healthy adult participants.
Primary Outcome
In addition to the number of participants who experience adverse events within the time frame of 28 days after each vaccination, all adverse events that occur from the signing of the informed consent through to the last study visit (Visit 10 \[Day 365\]) will be reported.
Conditions Studied
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL MVA Mosaic
Study Locations (1)
Massachusetts
- - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2014-09-23 |
| Est. Completion | 2015-11-30 |
| Phase | Phase 1 |
What the finished NCT02218125 record still lists
NCT02218125 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 25 participants, a relatively small participant target, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (96% lower).
The record links to 1 condition, with Healthy appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02218125 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT02218125 about?
NCT02218125 is a clinical study titled "A Phase I Study of an HIV Vaccine in Healthy, HIV Uninfected Adults". The purpose of this study is to assess the safety and tolerability of Modified Vaccinia Ankara (MVA) Mosaic vaccine in healthy adult participants.
What is the current status of trial NCT02218125?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 25 participants. The study started on 2014-09-23. Estimated completion is 2015-11-30.
What conditions does trial NCT02218125 study?
This clinical trial studies the following conditions: Healthy.
What interventions are being tested in trial NCT02218125?
The interventions under investigation include: Placebo (BIOLOGICAL), MVA Mosaic (BIOLOGICAL).
Who is sponsoring clinical trial NCT02218125?
This trial is sponsored by Crucell Holland, which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02218125 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02218125's enrollment target sits among peer trials
25 778th of 1090 higher than 301 of 1,090 other Healthy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Healthy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Assessment of Neuroinflammation in Central Inflammatory Disorders Using [F-18]DPA-714.
RECRUITING · Phase 1
-
A Study of LY3867070 in Healthy Participants
RECRUITING · Phase 1
-
A Study to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of AZD1613 in Healthy Participants.
RECRUITING · Phase 1
-
Evaluate the Pharmacokinetics, Safety, and Tolerability of NSHO-101 in Healthy Participants
RECRUITING · Phase 1
-
Comparison of the Short-Term Effect of Dietary Carbohydrate Restriction Versus Exogenous Ketone Supplementation on Myocardial Glucose Suppression and Timing to Achieve a State of Ketosis Using FDG PET/CT Serial Imaging
RECRUITING · Phase 1
-
A Study of V118E in Healthy Participants (V118E-003)
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01166854 · 25 participants
Characterization of Familial Myopathy and Paget Disease of Bone
- NCT01913106 · 25 participants · Phase 1
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
- NCT02138669 · 25 participants · NA
Intacs Prescription Inserts for Keratoconus Patients
- NCT02174549 · 25 participants · Phase 1
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI